Fasting and Fasting-Mimicking Diets Show Promise as Cancer Therapy Boosters

Cancer kills nearly 10 million people annually, and conventional therapies—chemotherapy, radiotherapy, immunotherapy—face persistent challenges of resistance and toxicity. This 2026 narrative review by Wali, published in the International Journal of General Medicine, asks whether fasting and fasting-mimicking diets (FMDs) could serve as safe, low-cost adjuncts that improve treatment outcomes while reducing harm to healthy tissue.

The review synthesizes 41 peer-reviewed studies identified via PubMed, PubMed Central, and Google Scholar (publications 2010–2025, with select landmark older studies). Three thematic domains were analyzed: biological rationale, molecular mechanisms, and clinical evidence.

The core biological insight is differential stress resistance (DSR) and differential stress sensitization (DSS). Normal cells, when deprived of nutrients, downregulate proliferative signaling and enter a protective, low-energy maintenance state. Cancer cells—locked into constitutive oncogenic signaling via PI3K/AKT/mTOR and driven by the Warburg effect (preferential aerobic glycolysis)—cannot make this adaptive shift, leaving them metabolically vulnerable. Fasting amplifies this disparity. At the molecular level, three key mechanisms are detailed: (1) Autophagy induction via the AMPK–mTORC1–ULK1 axis—nutrient deprivation raises AMP:ATP ratios, activates AMPK, suppresses mTORC1, and triggers autophagic recycling that cancer cells, with oncogene-suppressed autophagy, cannot adequately exploit for survival; (2) Warburg effect disruption—fasting reduces systemic glucose and IGF-1, suppressing HIF-1α-driven glycolytic gene expression (GLUT1, HK2), starving cancer cells of their preferred fuel while normal cells shift to fatty acid oxidation; (3) Oxidative stress modulation via the KEAP1–NRF2–ARE axis—fasting appropriately activates NRF2 in normal cells, upregulating antioxidant enzymes that protect healthy tissue from chemotherapy-induced ROS damage; cancer cells with constitutive NRF2 hyperactivation lose context-appropriate redox regulation, paradoxically increasing their vulnerability under fasting-enhanced oxidative conditions.

On the clinical side, early-phase trials are encouraging but preliminary. The DIRECT phase 2 multicentre trial found that cyclic FMD alongside neoadjuvant chemotherapy improved tumor responses in HER2-negative breast cancer without increased toxicity. The BREAKFAST phase 2 randomized trial showed a severely calorie-restricted 5-day FMD regimen is safe in early-stage triple-negative breast cancer (TNBC) patients receiving preoperative chemotherapy, with early downregulation of glycolytic pathways correlating with higher pathologic complete response rates. Across studies, FMDs consistently reduced circulating IGF-1 and glucose and favorably shifted immune cell populations in the tumor microenvironment.

Caveats are significant. Most trials involve small, heterogeneous cohorts with varying cancer types, fasting protocols, and concurrent treatments. There are legitimate concerns about malnutrition, muscle loss, and practical adherence—particularly in patients already at risk for cancer cachexia. Long-term safety and survival data remain absent. The review concludes that fasting and FMDs are mechanistically compelling and show early clinical promise, but confirmation requires larger, well-designed, phase 3 randomized controlled trials.